BioSpace News Archive

Fact.MR – A Market Research and Competitive Intelligence Provider: The global apheresis market is projected to grow by 2x during the forecast period between 2020 to 2025, estimates Fact.MR.

Valneva SE, a specialty vaccine company, announced positive homologous booster data from the Phase 1/2 study, of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.

RELIEF THERAPEUTICS Holding SA, announced that it has filed a Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission to register Relief as a reporting company under the Securities Exchange Act of 1934.

InnoSkel announced that it has been awarded an Innovation Passport under the UK Medicines and Healthcare products Regulatory Agency’s Innovative Licensing and Access Pathway, to pursue accelerated patient access for its first-in-class treatment for spondyloepiphyseal dysplasia congenita, a type II collagen disorder.

Mitotech S.A, a Luxembourg-based clinical-stage biotechnology company in ophthalmology, announced that the U.S. Food and Drug Administration has granted orphan drug designation for the company’s topical cardiolipin peroxidation inhibitor, Visomitin, for the treatment of Leber’s Hereditary Optic Neuropathy, a rare inherited condition that can lead to blindness.

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces ensifentrine met all safety objectives in a thorough QT study designed to evaluate effects, if any, of ensifentrine on cardiac conduction in healthy individuals.

Alligator Bioscience announced an update on the on-going clinical Phase I trial with the 4-1BB drug candidate ATOR-1017, which is developed as a tumor-directed therapy for metastatic cancer.

Nordic Nanovector ASA, a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, announces the appointment of Sandra Jonsson, PhD, MBA as Chief Operating Officer.

ONWARD Medical N.V., the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, announces it has completed enrollment in the Up-LIFT study, a pivotal trial to evaluate the safety and effectiveness of ARC Therapy to restore hand and arm function in people with spinal cord injury.

Synerkine Pharma B.V. announced that it has added EUR 3.5 million to its Series A funding.